Home › Research › Clinical safety
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Jean Marc Orgogozo, Sid Gilman, Jean‐François Dartigues, Bernard Laurent, Michèle Puel, Lachlan Kirby, P. Jouanny, Bruno Dubois, L. Eisner, Stephen S. Flitman, Bernard‐François Michel, Merçé Boada, Ana Frank, C. Hock. Neurology, 2003-07-08
Topic: Brain proteins, microglia and lab models
Plain-language summary
BACKGROUND: AD is characterized by cerebral deposition of beta-amyloid plaques with amyloid beta-peptide (Abeta) 42 as the major peptide constituent, along with neurofibrillary tangles and neuronal loss. In transgenic mice, active immunization against Abeta42 removes these plaques and improves cognitive function. A Phase I study in AD patients demonstrated good safety and tolerability of multiple injections of aggregated Abeta42 (AN1792) with QS-21 as adjuvant. METHODS: Three hundred seventy-two patients with mild to moderate AD were randomized to receive IM injections of AN1792 or placebo (4:1) at baseline and at months 1, 3, 6, 9, and 12 in a multicenter Phase II safety, tolerability, and pilot efficacy study. Dosing was terminated after four early reports of meningoencephalitis, but follow-up continued. The study remains blinded, and further results will be reported after its termination. RESULTS: Symptoms and laboratory findings consistent with meningoencephalitis occurred in 18 of 298 (6%) patients treated with AN1792 compared with 0 of 74 on placebo (p = 0.020). Sixteen of the 18 had received two doses, one had received one dose, and one had received three doses of the study drug before symptoms occurred. The median latency from the first and last injections to symptoms was 75 and 40 days. No case occurred later than 6 months after the first immunization. Anti-Abeta42 antibody titers were not correlated with the occurrence or severity of symptoms or relapses. Twelve patients recovered to or close to baseline within weeks, whereas six remain with disabling cognitive or neurologic sequelae. All 18 patients remain alive to date (December 31, 2002), 6 months to >1 year after symptom onset. CONCLUSIONS: Postvaccination meningoencephalitis occurred without clear relation to serum anti-Abeta42 antibody titers. Potential mechanisms such as T-cell and microglial activation may be responsible and are under consideration to develop a safer anti-Abeta immunotherapy for AD.
What this study adds
Evidence grade: Not rated
In a trial of 372 patients with mild to moderate Alzheimer's disease, meningoencephalitis (brain inflammation) occurred in 18 of 298 patients given the amyloid vaccine AN1792 (6%) and in none of 74 on placebo, and dosing was stopped. Twelve recovered to or close to baseline within weeks, while six were left with disabling cognitive or neurologic effects.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Orgogozo, J. M., Gilman, S., Dartigues, J., Laurent, B., Puel, M., Kirby, L., et al. (2003). Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology. https://doi.org/10.1212/01.wnl.0000073623.84147.a8
Vancouver
Orgogozo JM, Gilman S, Dartigues J, Laurent B, Puel M, Kirby L, et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology. 2003. doi:10.1212/01.wnl.0000073623.84147.a8. PMID: 12847155.
BibTeX
@article{orgogozo2003-12847155,
author = {Orgogozo, Jean Marc and Gilman, Sid and Dartigues, Jean‐François and Laurent, Bernard and Puel, Michèle and Kirby, Lachlan and Jouanny, P. and Dubois, Bruno and Eisner, L. and Flitman, Stephen S. and Michel, Bernard‐François and Boada, Merçé and Frank, Ana and Hock, C.},
title = {{Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization}},
journal = {Neurology},
year = {2003},
doi = {10.1212/01.wnl.0000073623.84147.a8},
pmid = {12847155},
url = {https://doi.org/10.1212/01.wnl.0000073623.84147.a8}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 14 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Why it matters
In a trial of 372 patients with mild to moderate Alzheimer's disease, meningoencephalitis (brain inflammation) occurred in 18 of 298 patients given the amyloid vaccine AN1792 (6%) and in none of 74 on placebo, and dosing was stopped. Twelve recovered to or close to baseline within weeks, while six were left with disabling cognitive or neurologic effects.
How this study scored 56/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported and studied in people because the record does not state it. We have no data on strength of evidence, so that was left out: it earned 53 of the 95 points we could judge it on, which is 56 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | — / 5 | No evidence rating recorded — left out of this score |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2003 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 7 / 7 | Cited 1,356 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 54.2 citations a year over 25 year(s) since 2003 |
| Impact for its field and year | 5 / 6 | Cited 39.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 3 / 4 | Cited 76 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author C. Hock: h-index 24 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Inserm: institution h-index 1,988 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 12847155) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 53 / 95 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 53 of the 95 points we could judge it on is 56 out of 100. |
| Total | 56 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Clinical safety from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.